NovaDigm Therapeutics Presents Positive Safety and Immunogenicity Data in a Second Phase 1 Study for NDV-3 Vaccine
--NDV-3 is the First "Cross-Kingdom" Vaccine Being Developed for Candida and Staph Infections--
GRAND FORKS, ND – May 7, 2012 – NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced the presentation of positive data for its NDV-3 vaccine program in a second Phase 1 study. The presentation was made at the 15th Annual Conference on Vaccine Research, sponsored by the National Foundation for Infectious Diseases and held in Baltimore, MD. NDV-3 is a vaccine being developed for the prevention and treatment of diseases caused by Candida and Staphylococcus aureus (including methicillin-resistant S. aureus, or MRSA). NDV-3 contains recombinant Als3, a surface adhesin/invasin from Candida albicans, which is the first vaccine antigen to demonstrate preclinical "cross-kingdom" protective efficacy against both fungal and bacterial pathogens. Results from the new study demonstrated that a single dose of NDV-3 with or without alum adjuvant was safe, well-tolerated and induced strong antibody and T-cell immune responses.
"The data from our second Phase 1 study confirms positive results from our initial Phase 1 study and shows that those receiving adjuvant-free NDV-3 had robust immune responses, as did those receiving NDV-3 with alum adjuvant," said Timothy Cooke, Ph.D., NovaDigm's Chief Executive Officer. "These results position us to begin Phase 2 efficacy studies with an optimized vaccine formulation and a Phase 1 safety database of 200 adults."
The second Phase 1 trial was a double-blind, placebo-controlled study in 160 healthy adults evaluating the safety, tolerability and immunogenicity of a single dose of three different formulations and two routes of administration. A dose of the vaccine containing 300 μg of Als3 was administered intramuscularly with and without alum adjuvant to assess the impact of the adjuvant. In the third vaccinated group, a dose of NDV-3 containing 30 μg of Als3 was administered intradermally without alum adjuvant.
Results from the study demonstrated the safety and tolerability of NDV-3 in all three vaccinated groups compared to the saline placebo group. All three vaccinated groups showed rapid increases in serum and vaginal immunoglobulin G (IgG) and immunoglobulin A1 (IgA1) antibodies by day 7 following vaccination, which peaked at day 14. The demonstration of vaginal antibody responses to NDV-3 may be important in preventing vaginal yeast infections caused by Candida albicans , which is the objective of a planned Phase 2 efficacy study. The majority of subjects that received NDV-3 also demonstrated significant Als3 -stimulated production of the T-cell cytokines IL-17A and IFN-γ between 7 and 14 days post-vaccination relative to subjects receiving placebo. The Phase 1 data were presented in an oral presentation titled, NDV-3, a Recombinant Vaccine for Candida and Staphylococcus aureus is Safe and Immunogenic in Healthy Adults, by John Hennessey, Ph.D., Vice President of R&D for NovaDigm, on Monday, May 7, 2012 at 3:30pm in a session entitled "Vaccine Candidates: Preclinical and Clinical Studies."
NDV-3 Development Program
NDV-3 is a prophylactic vaccine candidate containing a recombinant form of the Candida surface protein Als3, which facilitates Candida adherence to and invasion of human endothelial cells. This vaccine was developed as a result of research in the labs of NovaDigm's scientific founders at the LA BioMedical Research Institute at Harbor- UCLA Medical Center demonstrating that several members of the agglutinin-like sequence (Als) family of proteins induce protective immunity in preclinical models. NDV-3 is the first vaccine to demonstrate protective efficacy against both fungal and bacterial pathogens. Preclinical studies have shown that NDV-3 confers a high survival
rate following a challenge with highly virulent doses of one of several species of Candida or against one of several strains of S. aureus, including methicillin-resistant S. aureus (MRSA).
Medical Need
Candida is the third most common cause of nosocomial bloodstream infections. The incidence of candidiasis in the United States is at least 20 per 100,000 people, or over
60,000 infections per year, of which approximately 40% (24,000) are lethal despite antifungal treatment. Candida is also the fungus responsible for vaginal yeast infections
and the oral infection known as thrush. Historically, S. aureus was predominantly the cause of invasive infections occurring among individuals with immune deficiencies, or
those in hospital settings. However, an urgent concern is the recent explosion of drugresistant S. aureus infections among young and otherwise healthy individuals in the
community. S. aureus is now a common cause of skin infections and the CDC estimates that 12 million physician visits annually are due to suspected S. aureus or MRSA skin
infections. In 2008, there were an estimated 90,000 cases of invasive MRSA in the U.S., leading to 15,000 deaths (17% mortality).
About NovaDigm
NovaDigm is developing innovative vaccines to protect patients from fungal and bacterial infections, which can be life-threatening and drug-resistant. The Company's
founding scientists from the LA BioMedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) are recognized leaders in the field of infectious disease and the
emerging threat of "superbugs." NovaDigm's lead product candidate, NDV-3, targets Candida, a fungal pathogen, and S. aureus, including MRSA. Based in North Dakota
with additional research activities at LA BioMed, NovaDigm has received funding from Domain Associates, a leading health care venture capital firm, and collaborates with
multiple government agencies. www.novadigmtherapeutics.com.
Contact: Media
Timothy Cooke Kari Watson or Jennifer Conrad
NovaDigm Therapeutics MacDougall Biomedical Communications
701.757.5161 781.235.3060
[email protected]
[email protected]